MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$331K
Free Cash flow
-$17,558K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Interest income
Stock-based compensation
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Accretion of marketable securiti...
Accrued expenses
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-09-30
2025-06-30
Total operating expenses
84,304
-
Loss from operations
-84,304
-
Interest income
7,088
-
Other expense
-40
-
Total other (income) expense
7,048
-
Net loss
-22,829
-54,427
Depreciation
58
161
Amortization of right-of-use assets - operating
268
518
Stock-based compensation
4,601
9,606
Accretion of marketable securities, net
-1,063
-2,907
Prepaid expenses and other assets
-1,943
-1,988
Operating lease liabilities
-270
-500
Accounts payable
101
-2,236
Accrued expenses
-317
802
Net cash used in operating activities
-17,508
-46,995
Purchases of marketable securities, available-for-sale
34,774
53,348
Proceeds from maturities of marketable securities, available-for-sale
51,875
105,013
Purchases of property and equipment
50
58
Net cash provided by (used in) investing activities
17,051
51,607
Proceeds from exercise of stock options
203
-
Proceeds from issuance of common stock under employee stock purchase plan
0
68
Net cash provided by financing activities
203
68
Effect of exchange rates on cash, cash equivalents and restricted cash
-77
361
Net increase in cash, cash equivalents and restricted cash
-331
5,041
Cash and cash equivalents at beginning of period
28,235
-
Cash and cash equivalents at end of period
32,945
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
of marketable...
$51,875K
Proceeds from exercise of
stock options
$203K
Net cash provided by
(used in) investing...
$17,051K
Net cash provided by
financing activities
$203K
Canceled cashflow
$34,824K
Net increase in
cash, cash...
-$331K
Canceled cashflow
$17,254K
Stock-based compensation
$4,601K
Prepaid expenses and
other assets
-$1,943K
Amortization of right-of-use
assets - operating
$268K
Accounts payable
$101K
Depreciation
$58K
Interest income
$7,088K
Purchases of marketable
securities,...
$34,774K
Purchases of property and
equipment
$50K
Net cash used in
operating activities
-$17,508K
Canceled cashflow
$6,971K
Effect of exchange
rates on cash, cash...
-$77K
something is missing
$54,427K
Total other (income)
expense
$7,048K
Canceled cashflow
$40K
Net loss
-$22,829K
Canceled cashflow
$61,475K
Accretion of marketable
securities, net
-$1,063K
Accrued expenses
-$317K
Operating lease
liabilities
-$270K
Other expense
-$40K
Loss from operations
-$84,304K
Total operating
expenses
$84,304K
Buy us a coffee
Ventyx Biosciences, Inc. (VTYX)
Ventyx Biosciences, Inc. (VTYX)